- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Conductus ships first supercon probe
Conductus of Sunnyvale, CA, has made the first commercial shipmentof its SuperProtonnmr high-temperature superconducting probefor NMR spectroscopy. The probe, which is being distributed byVarian Associates as part of its Unity Inova spectrometer
Conductus of Sunnyvale, CA, has made the first commercial shipmentof its SuperProtonnmr high-temperature superconducting probefor NMR spectroscopy. The probe, which is being distributed byVarian Associates as part of its Unity Inova spectrometer system,was shipped to the National High Magnetic Field Lab at FloridaState University in Tallahassee.
SuperProtonnmr uses coils made of the high-temperaturesuperconductor yttrium barium copper oxide (SCAN 4/24/96). Conductusclaims that the probe is four times as sensitive as conventionalNMR probes, allowing the analysis of much smaller samples.
In other Conductus news, the company this month announced adistribution agreement with Nalorac, a Martinez, CA, manufacturerand distributor of NMR probes. The deal will expand the distributioncoverage available for Conductus' high-temperature superconductingprobes, as Nalorac supplies conventional NMR probes to all majorNMR manufacturers.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
